Comparing two chemotherapy combinations for untreated nasal-type lymphoma
Part of Cancer clinical trials.
This study compares two different combinations of chemotherapy drugs to see which works better for people with early-stage nasal-type or advanced-stage natural killer/T-cell lymphoma. The goal is to find a more effective treatment with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years old or older
- Have confirmed early-stage nasal-type or advanced-stage natural killer/T-cell lymphoma
- Must have at least one measurable tumor lesion (lymph node > 1.5 cm or other site > 1 cm)
- Able to perform daily activities with an ECOG score of 0-2
- Adequate blood cell counts, liver, and kidney function
- No active hepatitis B or C, HIV infection, or serious heart conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This trial tests a treatment plan that uses a combination of a chemotherapy drug (pegaspargase) and radiation therapy, adjusting the treatment based on how well the cancer responds. It aims to improve outcomes for people with early-stage NK/T-cell lymphoma while reducing side effects.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
Hear when a new NK-T-Cell Lymphoma, Extranodal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.